Company intelligence / Profile preview

Cancer Prevention Pharmaceuticals, Inc.

Tucson, Arizona, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Phase 3

Overview

CPP conducted a pivotal Phase 3 trial (CPP FAP-310) for CPP-1X/Sulindac in patients with familial adenomatous polyposis, but the trial did not achieve its primary endpoint as announced in May 2019.

Therapeutic areas: GastroenterologyOncologyRare Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

ivospemin

Phase 3

Indications: Pancreatic cancer, Ovarian cancer

2 more assets in the full pipeline.

Request access →

Partnerships

Mallinckrodt PlcPanbela Therapeutics, Inc.

Beyond the preview

Go deeper on Cancer Prevention Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cancer Prevention Pharmaceuticals, Inc..

Explore the full profile